linjc16/ctgov huggingface dataset:
Immunological Characteristics of Patients With PID and IBD

Study Overview
=================
Brief Summary
-----------------
The investigators wish to characterize alterations in the architecture and function of immune cells in patients with a primary immunodeficiency that also develop inflammatory bowel disease. In addition, The investigators' goal is to characterize the microbiome of these patients, in order to determine whether specific microbial alterations are related to inflammation.

Detailed Description
-----------------
The pathogenesis of inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis is complex and is thought to be related to genetic, environmental and microbial alterations that lead to a hyperactive/dysregulated immune system that mediates tissue damage. In rare cases, IBD can develop in patients with primary immunodeficiencies (PID) who develop severe, atypical or recurrent infections. The bowel disease in these patients can present after they develop infectious complications but also prior to that. The goal of the current study is to characterize immune function in patients with PID and IBD in order to identify alterations in pro-inflammatory and regulatory pathways. The investigators will obtain blood samples from PID patients with IBD in order to perform deep immune profiling using various techniques such as flow cytometry, ELISA and others. Moreover, the investigators wish to characterize the microbiome of these patients. This multi-disciplinary approach will advance our understanding why specific patients with an immunodeficiency develop an IBD-like phenotype.

Official Title
-----------------
Immunological Characteristics of Patients With Primary Immunodeficiencies and Inflammatory Bowel Diseases

Conditions
-----------------
Inflammatory Bowel Diseases, Primary Immune Deficiency Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age <18 years diagnosis of an immunodeficiency suspected or confirmed IBD Exclusion Criteria: none

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PID IBD patients<br>patients with an immunodeficiency and inflammatory bowel disease phenotype | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of immune cells | Frequency of pro- and anti-inflammatory immune cell subsets including functional analysis | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of stool microbiome | 16S analysis to identify changes in diversity and specific taxa | 3 years |
Management of Postoperative Pain Following Total Knee Arthroplasty by Using Acupuncture-moxibustion Therapy

Study Overview
=================
Brief Summary
-----------------
Orthopedic surgery is reportedly among the most painful surgical procedures. Surgical damage following major orthopedic surgery often involves a large, deep incision with considerable tissue dissection and muscle, bone, and vascular exposure. Post-operative pain after such surgery is exacerbated on movement or by reflex spasms of the muscles, which may delay mobilization, reduce satisfaction, prolong hospitalization, and possibly increase medical costs. We design a prospective randomized study for postoperative pain control following total knee arthroplasty.

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Procedure: acupuncture-moxibustion therapy
* Procedure: Regular therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed for surgery of osteoarthritis of knee ability to tolerate surgery under general anesthesia. Exclusion Criteria: refusal or the lack of mental ability to provide informed consent neuropathic pain or sensory disorders in the leg requiring surgery previous surgery of the knee joint coagulation abnormalities chronic opioid users known history of intolerance to acupuncture-moxibustion therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>acupuncture-moxibustion therapy | Procedure: acupuncture-moxibustion therapy<br> <br> |
| Active Comparator: Regular therapy<br>Regular therapy | Procedure: Regular therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain VAS score |  | pre-operaton, immediately post operation, postop 6hrs, postop 12hrs, postop 18hrs, postop 24hrs, post op 48hrs, postop 72hrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional score: SF-36 |  | Pre-operation, immediately post-operation, postop 6 weeks, postop 12 weeks |
tDCS in Patients With Disorders of Consciousness

Study Overview
=================
Brief Summary
-----------------
test

Detailed Description
-----------------
Neurostimulation techniques such as deep brain stimulation (DBS) and spinal cord stimulation (SCS) have been used to treat DOC. Although these techniques have been shown to increase patient response, there are still some limitations. For example, DBS requires craniotomy and may increase the risk of intracranial hemorrhage and infection. In addition, the complexity and cost of these technologies also limit their potential applications.

Official Title
-----------------
The Usage of tDCS in Patients With Disorders of Consciousness

Conditions
-----------------
Consciousness Disorder, Transcranial Direct Current Stimulation

Intervention / Treatment
-----------------
* Device: transcranial direct current stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with DOC: VS and MCS (the cause of unification is: traumatic brain injury, the course of more than 1 month, not more than 1 year ; age 18-65; Past history without a mental disorder; No previous alcohol or substance abuse; No epilepsy or frequent spontaneous movement; No benzodiazepines; No moderate or severe hydrocephalus, All patients were right handed. Exclusion Criteria: Exclusion of organic heart disease, such as sinus bradycardia, arrhythmia; exclusion of patients with intracranial metal devices, pacemakers or any other device.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: the treatment of transcranial direct current stimulation<br>Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes. | Device: transcranial direct current stimulation<br>* the treatment of transcranial direct current stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement of CRS-R | test | 7 days |
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Study Overview
=================
Brief Summary
-----------------
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Detailed Description
-----------------
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Official Title
-----------------
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Conditions
-----------------
Myelodysplastic Syndromes, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD)

Intervention / Treatment
-----------------
* Procedure: nonmyeloablative allogeneic hematopoietic cell transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- Myelodysplastic Syndromes Myeloproliferative Disorders HLA matched donor available Exclusion Criteria:- organ dysfunction HIV positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: nonmyeloablative allogeneic hematopoietic cell transplant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of transplant |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion |  | 1 year |
Bronchospasm Associated With High Nitric Oxide

Study Overview
=================
Brief Summary
-----------------
Intraoperative bronchospasm challenges anesthesia's safety. This study aims to investigate high concentration of exhaled nitric oxide as a marker of intraoperative bronchospasm.

Detailed Description
-----------------
Previous studies in asthmatic patients suggested that exhaled nitric oxide may represent a noninvasive measure for airway inflammation. Anesthesia information forms from 1999 throughout 2004 were revised (n=146.358). Bronchospasm occurrence appeared registered on 863 forms. From those, nine were identified as non-asthmatics patients (Bronchospasm group). Also, 12 asthmatics constituted one additional group (Asthma group) and 10 subjects with no previous airway disease or symptoms (Control group). All subjects were submitted to Exhaled nitric oxide measurements (parts/billion), spirometry and induced sputum.

Official Title
-----------------
Higher Exhaled Nitric Oxide (NO) is Associated With Intraoperative Bronchospasm

Conditions
-----------------
Asthma, Airway Hyperresponsiveness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with no systemic disease and registered bronchospasm during anesthesia induction Exclusion Criteria: hypertension, COPD, diabetes, pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bronchospasm<br>Patients who presented bronchospasm during anesthesia induction | |
| Asthma<br>Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics | |
| Control<br>Patients who were submitted to anesthesia induction and showed no complications | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exhaled nitric oxide in parts per billion |  | one to six months after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eosinophils concentration within sputum sample, pulmonary function tests |  | one to six months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nitric oxide, bronchospasm, anesthesia, induced sputum, asthma
Obesity Hypoventilation Syndrome Prevalence Study

Study Overview
=================
Brief Summary
-----------------
This is an observational study to characterize the prevalence of Obesity Hypoventilation Syndrome in patients referred to the sleep lab.

Official Title
-----------------
Obesity Hypoventilation Syndrome Prevalence Study

Conditions
-----------------
Obesity Hypoventilation Syndrome

Intervention / Treatment
-----------------
* Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
* Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Greater than or equal to 21 yrs. of age Referred to sleep lab for diagnostic PSG, initial titration PSG or split night PSG as routine clinical care BMI greater than or equal to 30kg/m2 Exclusion Criteria: Acutely ill or medically unstable to participate per PI Current positive airway pressure(PAP therapy)users Medical History of Chronic Obstructive Pulmonary Disease(COPD) Incapable of providing own informed consent BMI less than 30kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BMI greater than or equal to 30kg/m2 -venous<br>BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study. | Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.<br>* Venous blood gas, basic metabolic panel, PSG variable data collection.<br>|
| BMI greater than or equal to 30kg/m2 - arterial<br>BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study. | Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.<br>* Arterial blood gas, basic metabolic panel, PSG variable data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baseline venous blood draw | The study involves a venipuncture and data collection at the time of sleep study. Data collection will be correlated to blood draw results. | single blood draw |
Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer

Study Overview
=================
Brief Summary
-----------------
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the expression profiles for the two most important miRNA processing enzymes Dicer and Drosha of actinic keratoses, basal cell carcinoma and squamous cell carcinoma are compared to healthy skin tissue.

Official Title
-----------------
Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer

Conditions
-----------------
Skin Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with actinic keratoses, squamous cell carcinoma or basal cell carcinoma of the skin Exclusion Criteria: Patients under 18 years of age Patients with other forms of cancer in previous medical history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with actinic keratoses of the skin | |
| 2<br>Patients with basal cell carcinoma of the skin | |
| 3<br>Patients with squamous cell carcinoma of the skin | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients

Study Overview
=================
Brief Summary
-----------------
Assessment of the influence of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension patients.

Detailed Description
-----------------
Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Thiazide-type diuretics, angiotensin-converting enzyme (ACE) inhibitors and some of angiotensin-II receptor blockers (ARB) were reported to reduce renal excretion of urate and increased serum uric acid levels, Beta-blockers also elevate serum uric acid levels. Hyperuricemia is a risk factor for cardiovascular diseases. Hyperuricemia was found to correlate with hypertension excluding the influence of other factors such as age and renal function. Furthermore, many studies found that hyperuricemia was independently associated with cardiovascular events in patients treated with antihypertensive drugs. It is important to control serum uric acid levels in hypertensive patients treated with antihypertensive drugs in order to reduce the risk of gout and cardiovascular events. There is a gap in knowledge in studies showing the effect of antihypertensive drugs on serum uric acid in newly diagnosed hypertensive patients.

Official Title
-----------------
Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All newly diagnosed hypertensive patients aged 30 years old and above will be invited to participate in this study Exclusion Criteria: Patients below 30 years old. Patients with kidney disease. Patients who are taking medications known to increase SUA as (Thiazide and Loop diuretics, Salicylates, Cyclosporin use) or decrease the level of uric acid in the urine as (Allopurinol, Febuoxstate).

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension. | we will measure the change of the level of serum uric acid after 6 months from the treatment of antihypertensive durgs | 6 months from baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| obesity | it will be measured by BMI (kg/m2) | 6 months from baseline |
Oral and Maxillofacial Pathology in Pediatric Patients

Study Overview
=================
Brief Summary
-----------------
determination of the relative frequency of oral and maxillofacial pathological lesions among the Egyptian children and compare it with the global reports.

Detailed Description
-----------------
Oral and maxillofacial pathology in pediatric patients differs from the general population, as the nature of lesions in children changes with growth and development. Oral and maxillofacial pathology encompasses a wide spectrum of diseases, some of which (i.e. aphthous ulceration, geographic tongue, and herpes labialis) can be diagnosed on clinical presentation alone. For other soft tissue diseases and for pathology with bony components, incisional or excisional biopsy is mandatory to establish a definitive diagnosis . Several studies illustrated that oral and maxillofacial pathology in pediatric populations varies based on the geographic location of the population as racial and environmental specificities and the lifestyle of each population may influence the prevalence of these diseases . Although there is increasing literature regarding the incidence and prevalence of pediatric oral and maxillofacial pathology, there is no study investigating the range and frequency in Egyptian children.

Official Title
-----------------
A Retrospective Analysis of Oral and Maxillofacial Pathological Lesions in Egyptian Children

Conditions
-----------------
Mouth Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy records for children aged from 0 to 18 years Exclusion Criteria: Biopsy records for patients older than 18 Incomplete record regarding age, gender, location

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of oral and maxillofacial pathological lesions among Egyptian children | percentage of cases with oral pathological lesions | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral pathology